Liver Cancer: What's Close To The Market
Executive Summary
The treatment of liver cancer will have a makeover in coming months, with several products including Bristol’s Opdivo nearing the market for a disease that is often diagnosed late and where previously there have been few meaningful advances in therapy for many years. Two recently published reports from Datamonitor Healthcare have reviewed the disease and the R&D pipeline for the condition.
You may also be interested in...
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.